High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. uri icon

authors

  • Pourhassan, Hoda
  • Curtin, Peter
  • Armenian, Saro
  • Stein, Anthony
  • Forman, Stephen J
  • Marcucci, Guido
  • Pullarkat, Vinod
  • Nakamura, Ryotaro
  • Aldoss, Ibrahim
  • Yang, Dongyun
  • Afkhami, Michelle
  • Pillai, Raju
  • Ball, Brian
  • Al Malki, Monzr
  • Salhotra, Amandeep
  • Ali, Haris
  • Andrew Artz, MD, MS

publication date

  • January 1, 2022